Company news
Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) news
Biomarin Pharmaceutical Inc. news releases on 6ix. Latest, Oct 5, 2026: BioMarin Appoints Cara Bauer as Chief People Officer
Press releases & updates
BioMarin Appoints Cara Bauer as Chief People Officer
October 5, 2026
BioMarin Appoints Cara Bauer as Chief People Officer
October 4, 2026
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
October 2, 2026
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
October 1, 2026
Profluent Partners With BioMarin to Design Novel Medicines Using AI
September 30, 2026
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
September 14, 2026
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
September 9, 2026
BioMarin Announces Close of the Alesta Therapeutics Acquisition
September 1, 2026
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
August 29, 2026
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
August 18, 2026
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
August 10, 2026
BioMarin Reports Second Quarter 2026 Financial and Operating Results
August 6, 2026
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
July 30, 2026
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
July 27, 2026
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
July 13, 2026
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
June 16, 2026
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
May 20, 2026
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
May 18, 2026
BioMarin Reports First Quarter 2026 Financial and Operating Results
May 4, 2026
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
May 2, 2026
BioMarin Completes Acquisition of Amicus Therapeutics
April 27, 2026
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
April 27, 2026
BioMarin Announces Board Leadership Transition
April 21, 2026
Roctavian (BioMarin Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
March 13, 2026
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
March 12, 2026
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Geneti...
March 11, 2026
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
March 3, 2026
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
February 26, 2026
BioMarin to Participate in Four Upcoming Investor Conferences in March
February 23, 2026
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
February 23, 2026
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
February 17, 2026
BioMarin Announces Closing of Private Offering of Senior Notes
February 12, 2026
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
January 29, 2026
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
January 25, 2026
BioMarin Appoints Arpit Davé Chief Digital and Information Officer
January 12, 2026
Veeva and BioMarin Form Long-Term Strategic Partnership
January 7, 2026
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
January 7, 2026
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
December 19, 2025
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
November 10, 2025
FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
October 28, 2025
BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
October 26, 2025
BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
October 21, 2025
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
September 7, 2025
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
September 5, 2025
BioMarin to Participate in Upcoming Investor Conferences
August 26, 2025
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
August 3, 2025
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
July 31, 2025
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
July 21, 2025
BioMarin Announces Completion of Acquisition of Inozyme
June 30, 2025
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
June 23, 2025